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Abstract
Background The US Centers for Disease Control and
Prevention (CDC) guidelines and the World Health Organi-
zation (WHO) both recommend HIV testing in health-care
settings.However,neitherorganization providesprescriptive
details regarding how these recommendations should be
adapted into clinical practice in an emergency department.
Methods We have implemented an HIV-testing program in the
ED of a major academic medical center within the scope of the
Universal Screening for HIV Infection in the Emergency Room
(USHER) Trial—a randomized clinical trial evaluating the fea-
sibility and cost-effectiveness of HIV screening in this setting.
Results and conclusion Drawing on our collective experi-
ences in establishing programs domestically and interna-
tionally, we offer a practical framework of lessons learned
so that others poised to embark on such HIV testing
programs may benefit from our experiences.
Keywords HIV.Testing.Screening.
Emergencydepartment
Introduction
In the US, approximately 25% of the estimated 1 million
people living with HIV infection are unaware of their
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DOI 10.1007/s12245-009-0123-xdiagnosis. In response to these statistics, the Centers for
Disease Control and Prevention (CDC) and the US
Preventive Services Task Force (USPSTF) have offered
recommendations on HIV testing. The CDC suggests that
voluntary HIV testing be offered to adults ages 13–64 in all
health-care settings, including the emergency department
(ED) [2]. In contrast, the USPSTF strongly recommends
that clinicians screen all adolescents and adults at increased
risk for HIV infection, but makes no recommendation for or
against routine screening [3]. Routine HIV testing in the
Emergency Department is specifically mentioned in the
CDC guidelines because of the tendency of the ED to serve
a patient population who under-report their HIV risk and
may not undergo risk-based HIV testing in other health-
care settings. In one study, 41% of these late-testers were
diagnosed with AIDS within 1 year, and 79% of them had
other health-care visits with a diagnosis that would not have
prompted an HIV test under a risk-based approach. A
targeted testing program may result in missed opportunities
to screen many eligible individuals [4–6].
Without identification, HIV-infected patients lack access
to life-saving therapies and continue to transmit disease. The
American College of Emergency Physicians (ACEP)
responded to the CDC recommendations with an HIV policy
statement: “HIV screening must be: practical, feasible, not
interfere with the primary acute care mission, based on the
local prevalence, and integrated with the local health-care
system” [7]. Since then, numerous approaches to HIV
testing in the ED and ambulatory settings have already been
implemented with varying degrees of reported success,
measured by rates of test offering, test acceptance, receipt
of test results, false-positive test results, cases identified,
and confirmed linkage to appropriate care [8–23].
We designed and implemented an HIV testing program
within the Universal Screening for HIV Infection in the
Emergency Room (USHER) Trial, a randomized clinical
trial conducted at a tertiary care center intended to examine
ED provider-based testing versus HIV counselor-based
testing. As an NIH-funded Trial, USHER examined
numerous “best practice” approaches. In the implementa-
tion of such a program, there are many things to consider,
including staff engagement, test selection, protocol devel-
opment, education and training of personnel, and linkage to
care. Our objective is to describe the development and
implementation strategies of a large-scale routine HIV
testing program in the ED so that others poised to embark
on such programs may benefit from what we learned.
Getting started
The success of any ED-based HIV testing program relies
heavily on the investment of a designated “champion(s)”
who will lead the efforts within the ED community and
hospital. As efforts often mirror compensation, this leader-
ship role might ideally be a funded effort as a fraction of a
full-time employee (FTE). The program’s success will very
much rely on the passion that this person conveys toward
the HIV testing mission. His/her capacity for leadership,
action, and consensus within all aspects of the ED staff will
likely portend the program’s success.
A needs assessment within the community and the
patient population is also a helpful early step. What is the
HIV prevalence within the hospital catchment area? At that
prevalence, is there an unmet need for HIV testing services?
It is also helpful to understand the referral base for patients
who might be identified within the ED testing program. For
the newly identified HIV-infected patients, what is the wait
time for a new patient appointment? Is there clinical HIV
outpatient capacity to longitudinally care for them? Finally,
the implementation of such a program is largely facilitated
by dedicated funding support prior to its implementation.
During the needs assessment and analysis of current
services, the possible funding mechanisms for the project
may become evident. Can this information be shared with
hospital administrators to indicate a need for dedicated
resources toward the program? Draft budget proposals
should consider necessary resources for personnel (e.g.,
counselors, social workers), HIV test kits, training sessions
(often run by consultants), and confirmatory laboratory
expenses (if not covered under clinical care). The short- and
long-term sustainability of the HIV testing program often
relies on a dedicated funding source.
Early in the program development, it is helpful to engage
a comprehensive team required to ensure the necessary
support for success. The hospital administration leadership,
representatives from public affairs, and legal counsel may
facilitate funding, issues that might draw lay press attention,
and consent processes. Legal counsel may offer further
invaluable assistance to ensure compliance with state and
hospital regulations on patient confidentiality, name-based
reporting to the state, medical liability, patient record
documentation, and contractual issues.
Emergency department providers
The implementation of HIV testing within the ED impacts
all ED staff including departmental leadership, faculty,
residents, nurses, staff, social workers, and interpreters. As
such, each provider’s engagement, training, and under-
standing of their motivation is crucial to embark on such an
effort. When applicable, it might be helpful to approach the
leaders of each staff group individually (e.g., chair, clinical
director, residency director, nurse manager, and assistant
nurse manager) because of the differing impact the program
may have on their respective employees. In order to remain
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should be integrated with careful priority to patient care and
flow. The goal is therefore to assimilate the program within
(rather than layered on top of) the current standard ED
processes. If directly involved in the testing program, each
employee will want to know his/her expected role and its
effect on his/her current patient care responsibilities.
Consider requesting feedback from staff to modify the
testing protocol appropriately.
Infectious disease providers
Critical to the mission of an HIV testing program is the
capacity to link newly identified patients to care. As such,
the HIV testing program should be handled in close
collaboration with the infectious disease (ID) division that
will often provide the patient’s first follow-up visit. Early
discussions with ID collaborators often include issues
related to capacity (are there enough providers to serve
newly identified patients?) and linkage to care (how soon
can a patient identified in the program get a “new patient”
appointment?). The ID division often has helpful resources
that might be useful in the development of such protocols,
creating synergy within the collaboration.
Laboratory services personnel
The involvement of the clinical laboratory can help
facilitate compliance with HIV testing regulations. Engag-
ing laboratory services early will assist with decisions
regarding choice of tests (attributes and drawbacks of each).
It may be valuable to seek their expertise on important
items such as point of care testing, quality control
measures, and HIV confirmatory procedures. A rapid,
reliable, and laboratory compliant test should be the goal.
Patient satisfaction and flow in the ED often rely on
turn-around times for test results (both initial and confir-
matory); this may also be an important component of the
discussion with laboratory services.
The choice of tests
In selecting the most appropriate HIV test, the following
factors should be taken into consideration: health-care
setting, HIV prevalence, current hospital standards, costs
and available resources, laboratory preference, space
available to conduct point-of-care testing, test performance,
and turn-around time for results. This decision should be
made in the context of the initial program design, patient
flow, and previous experience and/or contracts with these
manufacturers, which may help facilitate staff training.
Since the use of other point of care tests, such as
fingerstick glucometers, have been helpful in expediting
care, a rapid HIV test may be the best test to use in a busy
health-care facility [24].
As decisions are being made regarding which test to use,
it is helpful to know the landscape of new Food and Drug
Administration (FDA)-approved rapid HIV screening tests
[22]. The FDA defines Clinical Laboratory Improvement
Amendment (CLIA)-waived tests as simple laboratory
examinations that use unprocessed specimens (whole blood
or oral fluid) and have an insignificant risk of yielding an
erroneous result [25, 26]. The FDA requires that sites using
CLIA-waived rapid HIV tests have a quality assurance
(QA) program in place. CLIA-waived tests are well suited
for use in the US because they can be performed by
individuals without formal training in clinical and non-
clinical sites. Furthermore, these tests offer patients nega-
tive or preliminary positive test results during the course of
their visit [26]. The decision to use a point-of-care test will
require a designated laboratory space in the ED, personnel
training, strict QA measures, and meticulous documenta-
tion. The advantages of point-of-care HIV testing are
decreased transit time, faster overall turnaround time, and
high frequency with which patients receive their test results.
These advantages should be weighed against the responsi-
bility of strict laboratory standard compliance [26].
There are six rapid tests available on the market. These
include: Oraquick ® ADVANCE™ Rapid HIV 1/2 Anti-
body Test (Orasure Technologies, Inc., Bethlehem, PA);
Uni-Gold™ Recombigen ® HIV (Trinity Biotech, Bray,
Ireland); Reveal G-3 Rapid HIV-1 (MedMira Laboratories,
Inc., Halifax, Nova Scotia, Canada); MultiSpot™ HIV-1/
HIV-2 test (BioRad Laboratories, Redmond, WA); Clear-
view ® HIV 1/2 Stat-Pak ®; Clearview ® HIV 1/2
(Chembio Diagnostic Systems, Inc., Medford, NY). The
reported sensitivity and specificity for the rapid FDA
CLIA-waived HIV tests approach 100%. Oraquick has a
sensitivity (95% CI) of 98.4–99.9% and a specificity (95%
CI) of 99.6–100%. Uni-Gold has a sensitivity (95% CI) of
99.5–100% and a specificity (95% CI) of 99.0–100%.
Reveal G-3 and MutiSpot are not CLIA-waived. Clearview
has a sensitivity (95% CI) of 98.9–100% and a specificity
(95% CI) of 99.6–100% [25, 26]. Higher than expected
rates of false-positivity have been reported, as reflected in
lower positive predictive values in areas of low HIV
prevalence [23, 27]. A preliminary positive test result
requires confirmation by a more specific test, typically the
Western blot. In one Boston-based ED experience, patients
with a reactive oral Oraquick HIV test had an 8- to 32-fold
increased odds of HIV infection compared with the pre-test
odds, despite a lower than anticipated test specificity [23].
The goal for HIV testing programs is to optimize the test
for the specific setting without compromising test reliability
for the patients [1, 26–29].
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Test choice will determine the kind of specimen required to
conduct the test. The specimen collection options for rapid
HIV tests are oral fluid, serum fingerstick, and venipunc-
ture. Test performance may vary by type of specimen
collected, and understanding the performance character-
istics of the test as they relate to specimen type is essential
[23]. Furthermore, different collection options may affect
patients’ willingness to be tested, where the test can be
developed, and the time that the patients will have to wait
for results [26, 30, 31].
Test kit reading window period
The majority of currently available rapid HIV tests require
that the test be conducted within 5 min of specimen
collection. This requirement necessitates that the test be
developed at the point of care, as there may be insufficient
time to deliver the specimen to a central laboratory. Once
the development process begins, however, tests also vary in
their reading windows. For example, the OraQuick test
takes a minimum of 20 min to develop, but may be read
within a 20–40 min reading window. A longer reading
window might enable a tester to step away, attend to
another issue, and return to read the result. Another test,
Reveal G-3 Rapid HIV-1, takes 3–5 min to conduct, but
should be read immediately. This key test feature is
helpful when considering the program design of whom the
test operators will be and how their other responsibilities
might distract them from reading the test result during the
valid window. A test result that is not read within the
specified time window should be considered invalid and
repeated.
Procedures for ordering and receiving HIV test kits
and controls
In a routine testing program, there is rapid test kit turnover.
Systems should be considered to ensure adequate kit/
control supplies and that they are utilized within their
designated shelf-life (kit/control shelf-life differs by man-
ufacturer but is generally 6–24 months). When choosing a
test kit, it is helpful to engage the manufacturer to
understand how the kits and controls are packaged (box
size), how they must be stored (some require refrigeration
and/or other temperature specifications), what the shelf-life
is for each, and what control practices are suggested. Most
manufacturers will recommend that with the arrival of new
kits, expiration dates should be examined and quality
assurance tests performed. Thus, having personnel respon-
sible to receive these kits and perform these tasks is
helpful.
College of American Pathology (CAP) certificate
In the US, a certification and quality assurance process
exists (which is adhered to by standard clinical laboratories)
for programs that choose point-of-care testing. To ensure
that laboratory tests such as rapid HIV tests are being
performed and interpreted correctly, the College of Amer-
ican Pathology (CAP) requires that test operators register
for a certification process and participate in an external
assessment of testing proficiency every 6 months [32]. This
process serves as an external control for the rapid HIV
testing conducted in the ED and is most often US hospital
policy. The certificate is needed prior to program initiation
and should be kept in the laboratory area.
Quality assurance measures
Quality management systems should be established in all
settings performing HIV testing in order to validate
standard operating procedures and confirm that testing
algorithms are aligned with national guidelines [1]. These
internal quality assurance measures help to ensure that the
laboratory tests are reliable and are performing according to
the manufacturers’ expectations. HIV test controls should
be specific to both manufacturer and test kit.
HIV test costs
Testing costs should be considered during budget prepara-
tion. The price per kit of rapid HIV tests ranges from $14-
$25 and may depend, in part, on negotiated hospital
laboratory agreements. The costs associated with the
controls and shipments of supplies are generally compara-
tively small. Patient volume and confirmatory algorithms
should also be considered [1].
Education and training
Training ED staff
Obtaining “buy-in” fromthe EDstaff ismostsuccessfulwhen
they are knowledgeable about the benefits of a routine HIV
testing program. Research suggests that ED health-care
providers generally feel uninformed about HIV testing and
welcome more information and resources on the topic [8, 33].
ED staff participants may enjoy meeting team members and
learning about the program, including the testing protocols
and patient resources. As an incentive, Continuing Education
Units for nurses who attend the program may be awarded.
Training sessions may include basic facts about HIV
transmission, local incidence/prevalence estimates, and
state-based ethical and legal issues surrounding HIV testing.
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testing sites and HIV-related websites. A program website, a
bulletin board, and a “frequently asked question” handout
may be used to supplement communication with staff.
Counseling and testing training of staff
Many departments of public health offer a course to certify
HIV counselors with training in the process of offering,
consenting, testing, and counseling patients prior to HIV
testing. The training for HIV Counseling, Testing, and
Referral (CTR) is a useful resource where training
participants receive a state-issued HIV counselor certificate.
Training helps those designated to conduct the test learn the
proper method to obtain a specimen, develop the rapid HIV
test, and ensure their competency in reading the results.
Space constraints within the ED
Because the ED may consist of urgent, non-urgent, fast
track, and observation units, patient care rooms may not be
always private.
Offering the test and ensuring privacy
HIV testing is a sensitive issue that should ideally be
conducted in a private space. To respect the patients’ right
to privacy, every effort should be made to present the testing
program information and informed consent in a private area.
Patients may be approached in the waiting room, triage, or
their patientcare rooms.In situations where ensuring privacy
is difficult, efforts should be made to use quiet voices or
point to, rather than read, sensitive text, especially in cases of
curtain barriers in place of walls. If the patient population is
predominantly non-English speaking, having a translator
available may diminish testing barriers.
Data collection and documentation in the testing program
Patients who consent for testing may inquire whether
participation will affect their care, their health-care providers
will be notified about their participation, and their test results
will be added to their medical records. These questions
should be addressed in the context of program development.
Consider collecting basic patient demographic information
such as age, gender, race/ethnicity, primary language, and if
applicable, the reason for refusing to participate.
Informed consent
HIV testing should be accompanied by basic pre-test
information to enable the patient to make an informed and
voluntary testing decision [1]. In the US, states vary on
their requirements for the HIV informed consent process
[34]. Knowledge of the current state law is important so
that these can be communicated back to the patient. Some
states (e.g., Massachusetts and New York) require written
informed consent while others require verbal consent with
documentation that this was obtained (e.g., California). In
response to the CDC guidelines, states are actively engaged
in changing state laws, and thus this process is a “moving
target” [34]. Regardless, all states now require that newly
HIV-diagnosed persons be reported by name; notification of
this policy to patients is generally part of the consent
process [34].
Test result delivery
As with the test offer and consent process, patients should
receive both non-reactive (negative) and reactive (prelimi-
nary positive) HIV test results privately. Every effort must
be made to ensure patient confidentiality regarding HIV test
results by limiting the number of health-care providers who
are made aware of the patients’ results.
What to do when a rapid HIV test is reactive (positive)
Reactive (positive) rapid HIV test result protocol
Reactive tests may often produce anxiety among the testers,
staff, and patients. A prescriptive plan regarding what to do
with a reactive result may allay such anxieties. A “Reactive
(Positive) Result Packet” (including mock scripts) may help
personnel with the delivery of results andprovide patients with
available resources for follow-up and linkage to care. Such a
packet may lead to standardization of this process and
minimizing confusion in the reactive result delivery process
(Table 1).
Table 1 Contents of a reactive (preliminary positive) rapid HIV test
result protocol packet
“How to deliver a reactive result” script
The rapid HIV test manufacturer package insert
General information sheet on HIV infection
Confirmatory test protocol
• Pre-printed laboratory requisition slips
Linkage-to-care protocol
• Person in charge of scheduling appointments
• Parking arrangements
• Maps to the location of the appointment
• Interpreter contact information
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If a rapid HIV test is used, reactive test results require
confirmation. An HIV diagnosis should not be delivered
based on rapid test results alone. The CDC recommends
that reactive rapid tests be confirmed using an HIV Western
blot [2, 29]. To maximize the information the patient
receives at his/her first follow-up appointment, consider
adding both a CD4 cell count and HIV RNA (viral load) to
the confirmation panel [23]. Recent research suggests that
confirmatory blood work is most often completed when
done in the ED [11].
Linkage-to-care protocol
The final critical piece of any comprehensive HIV testing
program is linkage to long-term HIV care. An appointment may
involve delivery of confirmatory blood test results and linkage
to care for newly identified patients. To maximize follow-up
rates, it is helpful to have a prescriptive plan in place that can be
easily followed by staff and is convenient for the patients. The
plan may include scheduling appointments, transportation and
parking arrangements, provision of maps to the clinic, and
interpreter availability when necessary. Patients are often most
comfortable if offered an appointment soon after the availability
of confirmatory results. When such results appear before the
designated appointment, it may be helpful to schedule an
interim phone call. For patients who fail to keep their appoint-
ments,adesignatedindividualshouldmakerepeatedattemptsto
discreetly reach the patient in person, by phone, and/or by mail.
Protocol for those who leave without test results
Even in the era of rapid HIV tests, occasionally patients
will leave the ED without receiving their HIV test results. It
is critical to have a plan addressing how these cases will be
handled for both negative and reactive results. Similar to
the linkage-to-care protocol, patients may be contacted by
phone, letters, and/or requests to return to the hospital
(especially for reactive cases or when a patient will be back
for other reasons). All attempts to reach the patient and
deliver test results should be carried out with the same
principles of privacy and confidentiality as if the patient
were present in the ED.
Other issues to consider
Manual of Operating Procedures
To keep protocols standard, and so that all shifts will have
access, it may be helpful to develop a Manual of Operating
Procedures (MOOP). This is a “live” document that details
protocols and algorithms, contains copies of all forms and
resources, and provides education and training materials. It
serves as a reference for all personnel and should be
reviewed by every new hire into the program.
Pilot testing
Prior to full program implementation, it may be helpful to
pilot the testing program. During this pilot period,
simulated scenarios will assist personnel with developing
responses to challenging situations. Pilots may occur during
busy and slow ED times and at all hours of the day. The
feedback received during these pilot periods may prove
invaluable during implementation.
Sustainability
To help the HIV testing program achieve long-term
sustainability, it is important to incorporate as many aspects
as possible of the program and its personnel in the daily
operations of the ED. For example, components such as
personnel hiring, education and training sessions, protocol
changes, and purchasing should become part of the daily
routine in the ED. Furthermore, frequent, perhaps quarterly,
evaluation is helpful to examine data including offer rates,
acceptance rates, test rates, newly identified cases, and,
ideally, the number of patients linked to care. Such crude
statistics are vital in demonstrating the benefits of the
program to future funders.
International implications
In contrast to the US, the HIV epidemic internationally is
more extensive and severe. Daily, approximately 6,800
people are infected with HIV, and more than 5,700 die
because of inadequate access to comprehensive HIV care
[35]. The impact of an HIV epidemic differs from country
to country. While the majority of developed countries have
low level HIV epidemics (defined by WHO and UNAIDS
as an HIV prevalence not exceeding 5% in any subpopu-
lation), a substantial number of developing countries have a
generalized HIV epidemic (classified as an HIV prevalence
of greater than 1% among pregnant women) [1]. According
to the WHO, the needs assessment and ultimately the
selection of priority interventions and target populations
should be based on an understanding of the country’s
epidemiology, health-care infrastructure, societal norms,
political will, and available resources [1]. HIV testing, one
of the WHO Priority Interventions, should target patients in
health facilities, communities, and specialized outreach
modalities such as mobile units [1]. Numerous international
HIV testing programs have been implemented and report a
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not all programs have been successful. A recent report of a
Lesotho program highlights the critical importance of
training, expansion of services goals, adequate funding,
and administrative capacity [39].
Implementation of routine HIV testing programs should be
tailored to the specific international setting conditions. In
developed countries with low-level HIV epidemics, many
components of the program described in this report could be
directly applicable to specific developed country settings. The
initiation of an HIV screening program will likely require
efforts similar to those of the US domestic programs and may
include: identifying a program “champion,” performing a
needs assessment, understanding the local culture and
population demographics, assessing the capacity of the local
health care to provide HIV treatment, obtaining buy-in from
the local leadership, and procuring sustainable funding. In
resource-limited settings with generalized HIV epidemics,
additional unique issues such as program costs and test
acceptability related to HIV stigma may inhibit such efforts.
Internationally, the choice of test manufacturer may be
influencedbyamultitudeoffactorsincluding:localregulation
by in-country ministries, heat stability, storage capacity, staff
training, and quality assurance measures. While the WHO
lists rapid HIV antibody tests as essential laboratory tests at
health centers and district hospitals, confirmation with the
“gold standard” serum EIA and Western blot is often
impossible. Consequently, serial (or parallel) rapid tests are
often conducted for confirmation [1, 28, 40]. In areas of low
prevalence, test users should be aware of the possibility of
false-positive results. In high-prevalence areas, administra-
tors should be aware that false-negative results may also
occur. Clinical suspicion in the face of a negative test should
prompt secondary testing [40]. Most importantly, because of
the numerous barriers to follow-up, HIV testing programs in
developed and developing countries should emphasize
linkage to care protocols that are coordinated among patients,
urgent care physicians, and HIV providers.
Conclusions
Based on our domestic and international experiences, an
HIV testing program in the ED is feasible with appropriate
infrastructure and longitudinal support. Although proof is
still needed that HIV screening will alter HIV prevalence
and incidence estimates over time, we describe a compre-
hensive and practical set of implementation strategies for a
rapid HIV testing program in the ED. We examine issues
related to the engagement of personnel, test choice, space,
training, and follow-up of reactive results, capitalizing on
our collective experiences in program establishment inter-
nationally [28] and domestically in urgent care centers [41],
inpatient settings [42], prisons [43], and now, emergency
departments [23]. Long-term sustainability requires further
research to examine ways of addressing funding sources for
these programs, eliminate medico-legal barriers, and im-
prove the access to care for those found to be HIV-infected.
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